If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Biden married Neilia Hunter, a student at Syracuse University, on August 27, 1966, after overcoming her parents' disinclination for her to wed a Catholic. Their wedding was held in a Catholic church in Skaneateles, New York. They had three children: Joseph R. "Beau" Biden III, Robert Hunter Biden, and Naomi Christina "Amy" Biden. A few weeks after Biden was elected senator, his wife Neilia and one-year-old daughter Naomi were killed in an automobile accident in Hockessin, Delaware, on December 18, 1972. Their sons Beau (aged 3) and Hunter (aged 2) were in the car and were taken to hospital with non-life-threatening injuries. He considered resigning to care for them, but Senate Majority Leader Mike Mansfield persuaded him not to. Biden contemplated suicide and was filled with anger and religious doubt. He wrote that he "felt God had played a horrible trick" on him and had trouble focusing on work. Biden met teacher Jill Tracy Jacobs in 1975 on a blind date. They married at the United Nations chapel in New York on June 17, 1977, and spent their honeymoon at Lake Balaton in the Hungarian People's Republic. Biden credits her with the renewal of his interest in politics and life. In 1981, the couple had a daughter, Ashley Biden, who is a social worker, activist, and fashion designer. Jill helped raise her stepsons, Hunter and Beau, who were seven and eight respectively at the time of her marriage.
=== Riken === While the JINR–LLNL collaboration had been studying fusion reactions with 48Ca, a team of Japanese scientists at the Riken Nishina Center for Accelerator-Based Science in Wakō, Japan, led by Kōsuke Morita had been studying cold fusion reactions. Morita had previously studied the synthesis of superheavy elements at the JINR before starting his own team at Riken. In 2001, his team confirmed the GSI's discoveries of elements 108, 110, 111, and 112. They then made a new attempt on element 113, using the same 209Bi + 70Zn reaction that the GSI had attempted unsuccessfully in 1998. Despite the much lower yield expected than for the JINR's hot fusion technique with calcium-48, the Riken team chose to use cold fusion as the synthesised isotopes would alpha decay to known daughter nuclides and make the discovery much more certain, and would not require the use of radioactive targets. In particular, the isotope 278113 expected to be produced in this reaction would decay to the known 266Bh, which had been synthesised in 2000 by a team at the Lawrence Berkeley National Laboratory (LBNL) in Berkeley. The bombardment of 209Bi with 70Zn at Riken began in September 2003. The team detected a single atom of 278113 in July 2004 and published their results that September:
Hancock, David (2001). The Mastiffs: The Big Game Hunters – Their History, Development and Future. Ducklington, Oxon: Charwynne Dog Features. ISBN 9780951780114. Fogle, Bruce (2009). The Encyclopedia of the Dog. New York: DK Publishing. ISBN 978-0-7566-6004-8. Encyclopædia Britannica (2019). "Mastiff: breed of dog". www.britannica.com. Encyclopædia Britannica, Inc. Retrieved 9 September 2019. Parker, Heidi G. (2012). "Chapter 3: The history and relationship of dog breeds". In Ostrander, Elaine A.; Ruvinsky, Anatoly (eds.). The Genetics of the Dog. Wallingford, Oxfordshire: CAPI books. pp. 38–53. ISBN 9781845939403. Oxford Dictionaries (2019). "Mastiff". Lexico.com. Oxford University Press. Retrieved 9 September 2019. Wynn, M. B. (1886). History of the Mastiff: Gathered from Sculpture, Pottery, Carvings, Paintings and Engravings. Melton Mowbray, William Loxley. ISBN 978-1-4465-4892-9. {{cite book}}: ISBN / Date incompatibility (help) Young, Amy; Bannasch, Danika (2007). "Chapter 4: Morphological variation in the dog". In Ostrander, Elaine A.; Giger, Urs; Lindblad-Toh, Kerstin (eds.). The Dog and its Genome. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. pp. 47–66. ISBN 9780879697815.
Sources: en.wikipedia.org
A topical medication is a medication applied to a particular place on or in the body. Most often, topical medications are applied to the skin or mucous membranes, via creams, foams, gels, lotions, or ointments. Many topical medications are epicutaneous, meaning that they are applied directly to the skin. Topical medications may also be inhalational, such as asthma medications, or applied to the surface of tissues other than the skin, such as eye drops applied to the conjunctiva, or ear drops placed in the ear, or medications applied to the surface of a tooth. The word topical derives from Greek τοπικός topikos, "of a place".
Since May 2017, Holick has been barred from evaluating or treating children by Boston Medical Center, which subsequently reported him to the Massachusetts Board of Registration in Medicine for "health care facility discipline", but is still allowed to evaluate children who are participating in his research project. Boston University has defended Holick's right to testify in courts, as part of his academic freedom. Holick has speculated that the dinosaurs may have died of rickets and osteomalacia caused by a lack of vitamin D in reduced sunlight. A paper on vitamin D to treat COVID-19 has been retracted.
De novo peptide sequencing for mass spectrometry is typically performed without prior knowledge of the amino acid sequence. It is the process of assigning amino acids from peptide fragment masses of a protein. De novo sequencing has proven successful for confirming and expanding upon results from database searches. As de novo sequencing is based on mass and some amino acids have identical masses (e.g. leucine and isoleucine), accurate manual sequencing can be difficult. Therefore, it may be necessary to utilize a sequence homology search application to work in tandem between a database search and de novo sequencing to address this inherent limitation. Database searching has the advantage of quickly identifying sequences, provided they have already been documented in a database. Other inherent limitations of database searching include sequence modifications/mutations (some database searches do not adequately account for alterations to the 'documented' sequence, thus can miss valuable information), the unknown (if a sequence is not documented, it will not be found), false positives, and incomplete and corrupted data. An annotated peptide spectral library can also be used as a reference for protein/peptide identification. It offers the unique strength of reduced search space and increased specificity.
Alprenolol, or alfeprol, alpheprol, and alprenololum (Gubernal, Regletin, Yobir, Apllobal, Aptine, Aptol Duriles), is a non-selective beta blocker as well as a 5-HT1A and 5-HT1B receptor antagonist, used in the treatment of angina pectoris. It is no longer marketed by AstraZeneca, but may still be available from other pharmaceutical companies or generically.
Sources: en.wikipedia.org
While the mobile phase in a LC system is a pressurized liquid, the MS analyzers commonly operate under high vacuum. Thus, it is not possible to directly pump the eluate from the LC column into the MS source. Overall, the interface is a mechanically simple part of the LC–MS system that transfers the maximum amount of analyte, removes a significant portion of the mobile phase used in LC and preserves the chemical identity of the chromatography products (chemically inert). As a requirement, the interface should not interfere with the ionizing efficiency and vacuum conditions of the MS system. Nowadays, most extensively applied LC–MS interfaces are based on atmospheric pressure ionization (API) strategies like electrospray ionization (ESI), atmospheric-pressure chemical ionization (APCI), and atmospheric pressure photoionization (APPI). These interfaces became available in the 1990s after a two-decade-long research and development process.
During the 2010s, the Moroccan mafia was widely talked about in Dutch and Belgian politics. After the assassination of Derk Wiersum, a lawyer with information about Ridouan Taghi, Geert Wilders expressed his discontent in the Dutch parliament.
Novichok (Russian: Новичо́к, lit. 'newcomer, novice, newbie') is a family of nerve agents, some of which are binary chemical weapons. The agents were developed at the GosNIIOKhT state chemical research institute by the Soviet Union and Russia between 1971 and 1993. Some Novichok agents are solids at standard temperature and pressure, while others are liquids. Dispersal of solid form agents is thought possible if in ultrafine powder state. Russian scientists who developed the nerve agents claim they are the deadliest ever made, with some variants possibly five to eight times more potent than VX, and others up to ten times more potent than soman. Iran has also been associated with the production of such chemical agents. In the twenty-first century, Novichok agents came to public attention after they were used to poison opponents of the Russian government, including in the attempted assassination of Sergei Skripal in the United Kingdom which resulted in the poisonings of 5 people and the death of an unrelated civilian in Amesbury (2018), as well as the poisoning of Alexei Navalny (2020). However, the use of Novichok domestically against Russian citizens has been known since at least 1995. In November 2019, the Organisation for the Prohibition of Chemical Weapons (OPCW), which is the executive body for the Chemical Weapons Convention (CWC), added the Novichok agents to "list of controlled substances" of the CWC "in one of the first major changes to the treaty since it was agreed in the 1990s" in response to the 2018 poisonings in the UK.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.